Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma

Medicine and Dentistry

• Homologous Recombination 100%
• Gene 83%
• Neoplasm 25%
• Survival Time 25%
• Immunotherapy 25%
• Immune Checkpoint Inhibitor 25%
• Transitional Cell Carcinoma 16%
• Analysis 16%
• Therapeutic Procedure 16%
• Patient 16%
• Athletic Training 8%
• Proportional Hazards Model 8%
• Immune Response 8%
• Cell Cycle 8%
• Overall Survival 8%
• Screening 8%
• Tumor Progression 8%
• Cancer Grading 8%
• Tumor Invasion 8%
• Clinical Feature 8%
• Survival Analysis 8%
• Progressive Disease 8%
• Cell Cycle Regulation 8%
• DNA Mismatch Repair 8%
• Principal Component Analysis 8%
• Clinical Prediction Model 8%
• Gene Co-Expression Network 8%
• Survival 8%
• Tissues 8%
• Prognosis 8%

Biochemistry, Genetics and Molecular Biology

• Homologous Recombination 100%
• Nested Gene 83%
• Sample 41%
• Survival Time 25%
• Mutation 16%
• Differential Gene Expression 16%
• Gene Expression Profiling 16%
• Immune Response 8%
• Screening 8%
• Cell Cycle 8%
• Cell Cycle Regulation 8%
• Overall Survival 8%
• Gene Signature 8%
• DNA Mismatch Repair 8%
• Growth 8%
• CXCL9 8%
• Cancer Grading 8%
• Survival 8%
• Training 8%
• Principal Component Analysis 8%

Neuroscience

• Homologous Recombination 100%
• Gene 83%
• Immunotherapy 25%
• Predictor 16%
• Cell Cycle 8%
• Cell Cycle Regulation 8%
• Survival Analysis 8%
• TP53 8%
• DNA Mismatch Repair 8%
• Nomogram 8%
• CXCL9 8%